window.dataLayer = window.dataLayer || []; function gtag(){dataLayer.push(arguments);} gtag('js', new Date()); gtag('config', 'G-4PR1PSYQLJ'); Skip to content

Welcome to Discover Pharma! Today is : September 20, 2026

  • News
  • Featured News Archives
    • 12 Days of Christmas
    • Women in Pharma
  • About Us
Contact Us

coronary artery disease

  • Clinical & Regulatory,Drug Discovery & Development,Pharmaceuticals and therapeutics,Research & Development,Therapeutic Areas

    Isomab data support safety of angiogenic approaches in coronary artery disease

    A systematic review of more than two decades of clinical [...]

    September 4, 2026
  • Clinical & Regulatory,Digital & Data,Medical devices,Research & Development,Therapeutic Areas

    Oxford research to explore AI stroke prediction from routine cardiac CT at ESC 2026

    University of Oxford-led research will examine whether artificial intelligence can [...]

    August 24, 2026
  • Clinical & Regulatory,Digital & Data,Medical devices,Research & Development

    Caristo Diagnostics’ CaRi-Heart coronary inflammation technology authorised by US FDA

    Caristo Diagnostics’ CaRi-Heart technology has received US FDA De Novo [...]

    July 30, 2026

Bringing you the latest industry news and insights every day

Registered Address: Discover Pharma Ltd, 1 Dartmouth Close, Brighton, BN2 4HZ, UK
Company Number: 16239596

  • About Us
  • Contact Us
  • Legal
    • Cookie Policy
    • Privacy Policy
    • Terms & Conditions
  • Author Guidelines
    • Pharmaceutical Author Guidelines
    • Press Release Advice
  • Advertise with Us
  • Media Kit Request

© 2026 Discover Pharma. All rights reserved • Developed by Hairy Goat Design

Page load link

Press “ESC” key to close

main menu
  • Home
  • News
  • About Us
  • Contact
recent posts
  • Sapience Therapeutics gets FDA clearance for ST316 FAP study
    Categories: Biotech & Pharma Business, Clinical & Regulatory, Drug Discovery & Development, Pharmaceuticals and therapeutics, Research & Development, Therapeutic Areas
  • EURneffy recommended for emergency anaphylaxis treatment in NHS Wales
    Categories: Clinical & Regulatory, Drug Delivery & Formulation, Pharmaceuticals and therapeutics, Therapeutic Areas
  • Lifebit awarded three-year NIHR BioResource research environment contract
    Categories: Biotech & Pharma Business, Digital & Data, Research & Development
get connected
This website uses cookies and third party services. See our Cookie Policy and Privacy Policy pages for details.
OK
Go to Top